Salient Surgical Technologies

About Salient Surgical Technologies

Salient Surgical Technologies Inc. operated as a medical technology firm focused on developing and marketing advanced energy devices to control bleeding during surgical procedures. Originally established in August 1999 as TissueLink Medical, the company secured an exclusive global license for a 'wet' electrode technology initially developed by Medtronic. This foundational relationship with Medtronic proved pivotal, as the medical device conglomerate participated in Salient's seven funding rounds over the subsequent decade.

The company's core business centered on its proprietary TRANSCOLLATION® technology, a method that utilizes a combination of radio-frequency energy and saline to seal soft tissue and bone. This process works by raising tissue temperatures to approximately 70°C, causing collagen proteins to swell and close blood vessels, thereby providing hemostatic sealing. Its primary product, the AQUAMANTYS® system, was sold to hospitals for use by surgeons in a variety of procedures, including orthopedic, spine, open abdominal, and thoracic surgeries. The business model involved selling these specialized devices that offered benefits such as reduced blood loss and improved surgical site visualization.

Under the leadership of President and CEO Joseph F. Army, Salient demonstrated significant growth, with revenue annualizing at approximately $100 million by 2011. The company's trajectory culminated in a major strategic transaction in July 2011, when Medtronic announced a definitive agreement to acquire Salient for a total value of $525 million. Given Medtronic's prior investments, the net value of the transaction was approximately $480 million. The acquisition was completed on August 31, 2011, and Salient was integrated into Medtronic's Surgical Technologies business within its Restorative Therapies Group.